Headlines about Cellectis (NASDAQ:CLLS) have trended somewhat positive recently, Accern Sentiment reports. The research firm identifies negative and positive media coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Cellectis earned a news sentiment score of 0.21 on Accern’s scale. Accern also gave media headlines about the biotechnology company an impact score of 46.338688523006 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
These are some of the news stories that may have impacted Accern’s analysis:
- Cellectis S.A. (CLLS) Receives “Hold” Rating from SunTrust Banks, Inc. (americanbankingnews.com)
- Cellectis SA Gets a Hold Rating from SunTrust Robinson $CLLS https://t.co/3BWwuXm1Qe (4-traders.com)
- Zoetis Inc. (ZTS) has a value of $63.57 per share While Cellectis SA (CLLS) is stand at $29.12 – Stocks Gallery (stocksgallery.com)
- Mathieu Simon, M.D. Cellectis’ EVP & Chief Operating Officer, to Serve as Interim Chief Medical Officer (finance.yahoo.com)
Shares of Cellectis (NASDAQ CLLS) opened at 29.54 on Thursday. Cellectis has a 52 week low of $16.09 and a 52 week high of $32.46. The firm’s market cap is $1.06 billion. The firm has a 50-day moving average of $28.13 and a 200 day moving average of $28.13.
Several analysts recently commented on the stock. SunTrust Banks, Inc. downgraded shares of Cellectis from a “buy” rating to a “hold” rating and reduced their target price for the stock from $35.00 to $20.00 in a report on Tuesday, September 5th. Wells Fargo & Company reaffirmed an “outperform” rating and set a $40.00 target price (up previously from $33.00) on shares of Cellectis in a report on Tuesday, September 5th. Jefferies Group LLC reaffirmed a “buy” rating and set a $47.00 target price on shares of Cellectis in a report on Tuesday, September 26th. Zacks Investment Research raised shares of Cellectis from a “hold” rating to a “buy” rating and set a $32.00 target price for the company in a report on Wednesday, July 19th. Finally, BidaskClub downgraded shares of Cellectis from a “buy” rating to a “hold” rating in a report on Tuesday, July 25th. One analyst has rated the stock with a sell rating, two have given a hold rating and six have issued a buy rating to the company. Cellectis presently has a consensus rating of “Buy” and an average target price of $39.00.
Cellectis Company Profile
Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development and commercialization of rational genome engineering technologies. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement.
What are top analysts saying about Cellectis S.A.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Cellectis S.A. and related companies.